Apellis Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
100 5th Ave, Waltham, Massachusetts, 024...Phone Number
(617) 977-5700Website
www.apellis.comRevenue
$1.1 BillionStock Symbol
APLSIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
6
1
2
2
1
1
About Apellis Pharmaceuticals
Established in 2009, Apellis is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a broad range of life-threatening or debilitating autoimmune diseases based upon complement immunotherapy through the inhibition of the complement system at the level of C3. They are based in Waltham, Massachusetts.Explore more
Apellis Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Apellis Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Apellis Pharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if Apellis Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Apellis Pharmaceuticals
Click to see if Apellis Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when Apellis Pharmaceuticals launches new products
Funding: Get notified immidiatlly once Apellis Pharmaceuticals has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Apellis Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Apellis Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Apellis Pharmaceuticals
Find more new buyers
Compare Similar Companies to Apellis Pharmaceuticals
Compare insights from companies similar to Apellis Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Apellis Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Apellis Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Apellis Pharmaceuticals.
Apellis Pharmaceuticals financials insights
Gather financial insights about Apellis Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Angel/Seed
$1.7M
2011
Series A
$3M
2013
Series B
$6M
2014
Private Equity
$17.8M
Series C
$33M
2016
Series D
$47.1M
2017
Series E
$60M
Stock Offering
$150M
2021
Stock Offering
$402.5M
Apellis Pharmaceuticals Tech Stack
A closer look at the technologies used by Apellis Pharmaceuticals
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Apellis Pharmaceuticals News & Media
Shareholder Alert: Ademi LLP investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apellis (NASDAQ: APLS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Biogen.Apellis Pharmaceuticals (APLS) Hits 2-Year High on 140% Upside from Biogen Merger
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the 10 Stocks Dominating Today’s Market Surge. Apellis Pharmaceuticals climbed to a new two-year high on Tuesday, as investors gobbled up shares following news that it was set to be acquired by Biogen Inc. at a 140-percent upside. In intra-day trading, the stock soared to its highest price […]Apellis Pharmaceuticals Gains Boost from Analysts and Leadership Changes
Apellis Pharmaceuticals Inc.’s stocks have been trading up by 135.75 percent, driven by promising FDA designations and results. Key Takeaways Roth Capital’s positive views on Syfovre demand led to a Buy rating and a promising price target. Apellis Pharmaceuticals strengthens R&D capabilities with the addition of Mikael Dolsten. Positive long-term market share trends identified for […]Cantor Fitzgerald Cuts PT on Apellis Pharmaceuticals (APLS) to $31 From $35 – Here’s Why
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the best high growth healthcare stocks to buy now. Cantor Fitzgerald cut the price target on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) to $31 from $35 on March 13, reiterating an Overweight rating on the shares and telling investors in a research note that it updated its model after the fiscal […]
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Apellis Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Established in 2009, Apellis is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a broad range of life-threatening or debilitating autoimmune diseases based upon complement immunotherapy through the inhibition of the complement system at the level of C3. They are based in Walt... Read More
